Advances in lipid-lowering effect of PPARα agonists

HU Yue; XU Jun; LIU Yanhua; WANG Zengtao; HUANG Liming; FANG Jialong; WANG Chen

doi:10.11665/j.issn.1000-5048.20160118

Journal of China Pharmaceutical University > 2016 > 47(1): 118-124. > DOI: 10.11665/j.issn.1000-5048.20160118

HU Yue, XU Jun, LIU Yanhua, WANG Zengtao, HUANG Liming, FANG Jialong, WANG Chen. Advances in lipid-lowering effect of PPARα agonists[J]. Journal of China Pharmaceutical University, 2016, 47(1): 118-124. DOI: 10.11665/j.issn.1000-5048.20160118

Citation:

PDF (1038 KB)

Advances in lipid-lowering effect of PPARα agonists

More Information

Graphical Abstract

Abstract

Abstract

Peroxisome proliferator-activated receptor α(PPARα)is an important subtype in the PPARs family, which are a group of nuclear hormone receptors belonging to type II nuclear receptor super family. PPARα agonists, which used in the treatment of hyperlipemia in clinic, mainly include natural and synthetic types. According to the structure, the synthetic PPARα agonists can be divided into phenyl-heterocyclic derivatives, ureide derivatives, amide derivatives, phenyloxazole or phenylthiazole derivatives, etc. Up to now, many PPARα agonists have been approved or in clinical development, and a series of novel PPARα agonists with higher activity and selectivity are being developed. This review will summarized the progress in PPARα agonists according to their structural classification.
- peroxisome proliferator-activated receptor α,
- agonists,
- reducing blood lipid,
- progress

FullText(HTML)

References (39)

References

[1]	Kersten S.Integrated physiology and systems biology of PPARα[J].Mol Metab,2014,3(4):354-371.
[2]	Zeng ZY,Liao GH,Lu YF,et al.Research progress of PPARα agonists on cardiovascular and cerebrovascular diseases[J].Chin J Med Chem,2014,24(2):147-156.
[3]	Issemann I,Green S.Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators[J].Nature,1990,347(6294):645-650.
[4]	Gilde AJ,Fruchart JC,Staels B.Peroxisome proliferator-activated receptors at the crossroads of obesity,diabetes,and cardiovascular disease[J].J Am Coll Cardiol,2009,48(9):1-9.
[5]	Esmaeli S,Allameh A,Soleimani M,et al.The role of albumin and PPAR-α in differentiation-dependent change of fatty acid profile during differentiation of mesenchymal stem cells to hepatocyte-like cells[J].Cell Biochem Funct,2014,32(5):410-419.
[6]	Lannutti F,Marrone A,Re N.Prediction of the PPARα agonism of fibrates by combined MM-docking approaches[J].J Mol Graph Model,2011,29:865-875.
[7]	Pawlak M,Lefebvre P,Staels B.Molecular mechanism of PPARα action and its impact on lipid metabolism,inflammation and fibrosis in non-alcoholic fatty liver disease[J].J Hepatol,2015,62(3):1-14.
[8]	Huang J,Das SK,Jha P,et al.The PPARα agonist fenofibrate suppresses B-cell lymphoma in mice by modulating lipid metabolism[J].Biochim Biophys Acta,2013,1831(10):1555-1565.
[9]	Wu C,Jia Y,Lee JH,et al.trans-Caryophyllene is a natural agonistic ligand for peroxisome proliferator-activated receptor-α[J].Bioorg Med Chem Lett,2014,24(14):3168-3174.
[10]	Lee JH,Jun HJ,Hoang MH,et al.Catalposide is a natural agonistic ligand of peroxisome proliferator activated receptor-α[J].Biochem Biophys Res Commun,2012,422(4):568-572.
[11]	Jia Y,Bhuiyan MJ,Jun HJ,et al.Ursolic acid is a PPARα agonist that regulates hepatic lipid metabolism[J].Bioorg Med Chem Lett,2011,21(9):5876-5880.
[12]	Jia Y,Kim JY,Jun HJ,et al.Cyanidin is an agonistic ligand for peroxisome proliferator-activated receptor-alpha reducing hepatic lipid[J].Biochim Biophys Acta,2013,1831(4):698-708.
[13]	Goto T,Takahashi N,Kato S,et al.Bixin activates PPARα and improves obesity-induced abnormalities of carbohydrate and lipid metabolism in mice[J].J Agric Food Chem,2012,60(48):11952-11958.
[14]	Goto T, Kim YI, Funakoshi K, et al. Farnesol, an isoprenoid, improves metabolic abnormalities in mice via both PPARα-dependent and -independent pathways[J].Am J Physiol Endocrinol Metab,2011,301(5):1022-1032.
[15]	Lamers C,Dittrich M,Steri R,et al.Molecular determinants for improved activity at PPARα:structure-activity relationship of pirinixic acid derivatives,docking study and site-directed mutagenesis of PPARα[J].Bioorg Med Chem Lett,2014,24(16):4048-4052.
[16]	Jia Y,Kim JH,Nam B,et al.The dipeptide H-Trp-Arg-OH(WR)Is a PPARα agonist and reduces hepatic lipid accumulation in lipid-loaded H4IIE cells[J].Appl Biochem Biotechnol,2015,175(2):1211-1220.
[17]	Shi GQ,Dropinski JF,Zhang Y,et al.Novel 2,3-dihydrobenzofuran-2-carboxylic acids:highly potent and subtype-selective PPARα agonists with potent hypolipidemic activity[J].J Med Chem,2005,48(17):5589-5599.
[18]	Desai RC, Metzger E, Santini C, et al. Design and synthesis of potent and subtype-selective PPARα agonists[J].Bioorg Med Chem Lett,2006,16(6):1673-1678.
[19]	Fruchart JC.Selective peroxisome proliferator-activated receptor α modulators(SPPARMα):the next generation of peroxisome proliferator-activated receptor α-agonists[J].Cardiovasc Diabetol.,2013,12(82):2-8.
[20]	Liu ZM,Hu M,Chan P,et al.Early investigational drugs targeting PPAR-α for the treatment of metabolic disease[J].Expert Opin Investig Drugs,2015,24(5):611-621.
[21]	Sahebkar A, Chew GT, Watts GF. New peroxisome proliferator-activated receptor agonists:potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease[J].Expert Opin Pharmacother,2014,15(4):493-503.
[22]	Brown PJ,Stuart LW,Hurley KP,et al.Identification of a subtype selective human PPARalpha agonist through parallel-array synthesis[J].Bioorg Med Chem Lett,2001,11(9):1225-1227.
[23]	Solingapuram Sai KK,Kil KE,Tu Z,et al.Synthesis,radiolabeling and initial in vivo evaluation of[¹¹C]KSM-01 for imaging PPARα receptors[J].Bioorg Med Chem Lett,2012,22(19):6233-6236.
[24]	Matthews JM,Chen X,Cryan E,et al.Design and synthesis of indane-ureido-thioisobutyric acids:a novel class of PPARα agonists[J].Bioorg Med Chem Lett,2007,17(24):6773-6778.
[25]	Miyachi H, Nomura M, Tanase T, et al. Design,synthesis and evaluation of substituted phenylpropanoic acid derivatives as peroxisome proliferator-activated receptor(PPAR)activators:novel human PPARα-selective activators[J].Bioorg Med Chem Lett,2002,12(1):77-80.
[26]	Sierra ML,Beneton V,Boullay AB,et al.Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARalpha agonists.1.Discovery of a novel series of potent HDLc raising agents[J].J Med Chem,2007,50(4):685-695.
[27]	Faucher N,Martres P,Laroze A,et al.Design,synthesis and evaluation of trifluoromethane sulfonamide derivatives as new potent and selective peroxisome proliferator-activated receptor alpha agonists[J].Bioorg Med Chem Lett,2008,18(2):710-715.
[28]	Ban S,Kasuga J,Nakagome I,et al.Structure-based design,synthesis,and nonalcoholic steatohepatitis(NASH)-preventive effect of phenylpropanoic acid peroxisome proliferator-activated receptor(PPAR)α-selective agonists[J].Bioorg Med Chem,2011,19:3183-3191.
[29]	Wagner JD,Shadoan MK,Zhang L,et al.A selective peroxisome proliferator-activated receptor alpha agonist,CP-900691,improves plasma lipids,lipoproteins,and glycemic control in diabetic monkeys[J].J Pharmacol Exp Ther,2010,333(3):844-853.
[30]	Askari B,Wietecha T,Hudkins KL,et al.Effects of CP-900691,a novel peroxisome proliferator-activated receptor α,agonist on diabetic nephropathy in the BTBR ob/ob mouse[J].Lab Invest,2014,94(8):851-862.
[31]	Aoki T,Asaki T,Hamamoto T,et al.Discovery of a novel class of 1,3-dioxane-2-carboxylic acid derivatives as subtype-selective peroxisome proliferator-activated receptor alpha(PPARalpha)agonists[J].Bioorg Med Chem Lett,2008,18(6):2128-2132.
[32]	Asaki T,Aoki T,Hamamoto T,et al.Structure-activity studies on 1,3-dioxane-2-carboxylic acid derivatives,a novel class of subtype-selective peroxisome proliferator-activated receptor alpha(PPARalpha)agonists[J].Bioorg Med Chem,2008,16(2):981-994.
[33]	Nomura M,Yumoto K,Shinozaki T,et al.Discovery of cyclic amine-substituted benzoic acids as PPARα agonists[J].Bioorg Med Chem Lett,2012,22(1):334-338.
[34]	Schäfer HL,Linz W,Falk E,et al,AVE8134,a novel potent PPARα agonist,improves lipid profile and glucose metabolism in dyslipidemic mice and type 2 diabetic rats[J].Acta Pharmacol Sin,2012 33(1):82-90.
[35]	Xu Y,Mayhugnd D,Saeed A,et al.Design and synthesis of a potent and selective triazolone-based peroxisome prolife-rator-activated receptor α agonist[J].J Med Chem,2003,46(24):5121-5124.
[36]	Khera AV,Millar JS,Ruotolo G,et al.Potent peroxisome proliferator-activated receptor-α agonist treatment increases cholesterol efflux capacity in humans with the metabolic syndrome[J].Eur Heart J,2015,25(6):291-295.
[37]	Mizuno CS, Ma G, Khan S, et al. Design, synthesis, biological evaluation and docking studies of pterostilbene analogs inside PPAR[J].Bioorg Med Chem,2008,16(7):3800-3808.
[38]	Sauerberg P,Mogensen JP,Jeppesen L,et al.Design of potent PPARalpha agonists[J].Bioorg Med Chem Lett,2007,17(11):3198-3202.
[39]	Pingali H,Jain M,Shah S,et al.Design and synthesis of novel bis-oximinoalkanoic acids as potent PPARalpha agonists[J].Bioorg Med Chem Lett,2010,20(3):1156-1161.

[1]	CAI Xu, WU Xiaoqian, HAN Lingfei, FENG Feng, QU Wei, LIU Wenyuan. Research progress on natural products regulating osteogenic differentiation[J]. Journal of China Pharmaceutical University, 2025, 56(1): 10-21. DOI: 10.11665/j.issn.1000-5048.2024101003
[2]	LU Lixue, WANG Yonghui. Progress in discovery of RORγt inverse agonists for the treatment of autoimmune diseases[J]. Journal of China Pharmaceutical University, 2024, 55(1): 87-102. DOI: 10.11665/j.issn.1000-5048.2023121303
[3]	LU Zhipeng, XU Qinglong, CHEN Panpan, QIN Yajuan, TANG Lijun, LI Tingyou. Research progress of radioprobes targeting fibroblast activating protein[J]. Journal of China Pharmaceutical University, 2022, 53(6): 651-662. DOI: 10.11665/j.issn.1000-5048.20220603
[4]	YANG Qian, CHEN Nannan, YOU Qidong, XU Xiaoli. Research progress on stimulator of interferon genes (STING) agonists[J]. Journal of China Pharmaceutical University, 2022, 53(3): 253-263. DOI: 10.11665/j.issn.1000-5048.20220301
[5]	JI Liyang, HAO Jing, WANG Guocheng, XIE Weijia. Research progress on stimulator of interferon genes agonists for cancer immunotherapy[J]. Journal of China Pharmaceutical University, 2020, 51(1): 1-9. DOI: 10.11665/j.issn.1000-5048.20200101
[6]	WANG Chen, XU Jun, LIU Yanhua, WANG Zengtao, HU Yue, TIAN Taiping, YI Mengjuan. Research progress on functionalized graphene oxide as drug carriers[J]. Journal of China Pharmaceutical University, 2017, 48(1): 117-124. DOI: 10.11665/j.issn.1000-5048.20170118
[7]	ZHANG Danfeng, JIAO Yu, LIU Yong, ZHANG Yanmin, ZHANG Zhimin, LU Tao. Progress of small molecule anti-tumor covalent drugs[J]. Journal of China Pharmaceutical University, 2017, 48(1): 1-7. DOI: 10.11665/j.issn.1000-5048.20170101
[8]	HU Yue, CHEN Zhou, LUO Xiaoxing, XUE Xiaoyan. Research progress of 1, 2-dilinoleyloxy-3-dimethylaminopropane-based cationic lipid nanoparticle[J]. Journal of China Pharmaceutical University, 2016, 47(1): 112-117. DOI: 10.11665/j.issn.1000-5048.20160117
[9]	ZHANG Jinghui, WANG Yajing, HU Rong. Roles of Moesin in tumor progression[J]. Journal of China Pharmaceutical University, 2015, 46(3): 371-375. DOI: 10.11665/j.issn.1000-5048.20150319
[10]	ZHANG Qian, CHEN Cen, YANG Fengqing, XIA Zhining. Mechanism of agonist-induced platelet activation and research progress of anti-platelet drugs[J]. Journal of China Pharmaceutical University, 2014, 45(6): 632-648. DOI: 10.11665/j.issn.1000-5048.20140604

Cited By

Get Citation

PDF

XML

Article views (1574) PDF downloads (2820)

Turn off MathJax

Article Contents

Abstract

References

Advances in lipid-lowering effect of PPARα agonists

Abstract

References

Related Articles

Catalog

Advances in lipid-lowering effect of PPARα agonists

Abstract

References

Related Articles

Catalog

Export File

Citation

Format

Content